Skip to content

20-310 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

Status: open

An Open-label Extension of Study M15-741 to Evaluate the Safety and Tolerability of 24-hour Daily Exposure of Continuous Subcutaneous Infusion of ABBV-951 in Subjects With Parkinson's Disease

Treatment for Parkinson's Disease

Contact Us


This is an extension study to the M15-736 trial for those participating in that trial. Patients who met criteria to enroll in the parent trial also meet criteria to participate in this 96 week long term safety study of the 24 hour continuous infusion of ABBV-951.


This trial is sponsored by AbbVie.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

    This link will open in a new tab or window.